Circulating Extracellular Vesicles Are Strongly Associated With Cardiovascular Risk Markers

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Jun 13

PMID 35694679

Authors

Ruihan Zhou

Esra Bozbas

Keith Allen-Redpath

Parveen Yaqoob

Affiliations

Soon will be listed here.

Abstract

Background: Extracellular vesicles (EVs) are submicron membrane-bound vesicles released from various cells, which are emerging as a potential novel biomarker in cardiovascular diseases (CVDs) due to their procoagulatory and prothrombotic properties. However, there is little information about the relationships between circulating EVs and conventional and thrombogenic risk markers of CVDs.

Objective: To investigate the relationships between circulating EVs, conventional cardiovascular risk markers and thrombogenic markers in subjects with moderate risk of CVDs.

Design: Subjects ( = 40) aged 40-70 years with moderate risk of CVDs were recruited and assessed for body mass index, blood pressure and plasma lipid profile, as well as platelet aggregation, clot formation, thrombin generation and fibrinolysis. Numbers of circulating EVs were assessed by Nanoparticle Tracking Analysis and flow cytometry. A range of assays were used to assess the procoagulatory activity of plasma and circulating EVs.

Results: Circulating EV numbers were positively associated with body mass index, blood pressure, plasma triacylglycerol concentration and overall CVD risk. Higher circulating EV numbers were also associated with increased thrombin generation and enhanced clot formation, and EVs isolated from subjects with moderate CVD risk promoted thrombin generation . Higher numbers of endothelial-derived EVs were associated with a greater tendency for clot lysis. Plasma triacylglycerol concentration and diastolic blood pressure independently predicted circulating EV numbers, and EV numbers independently predicted aspects of thrombin generation and clot formation and 10-year CVD risk.

Conclusion: Circulating EVs were strongly associated with both conventional and thrombogenic risk markers of CVDs, and also with overall CVD risk, highlighting a potentially important role for EVs in CVDs.

Citing Articles

Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling.

Habibi A, Ruf W, Schurgers L Cell Commun Signal. 2025; 23(1):57.

PMID: 39891111 PMC: 11786455. DOI: 10.1186/s12964-025-02066-6.

Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery.

Weiss L, Macleod H, Maguire P Curr Opin Hematol. 2024; 32(1):4-13.

PMID: 39377239 PMC: 11620325. DOI: 10.1097/MOH.0000000000000845.

Dietary n-3 polyunsaturated fatty acids alter the number, fatty acid profile and coagulatory activity of circulating and platelet-derived extracellular vesicles: a randomized, controlled crossover trial.

Bozbas E, Zhou R, Soyama S, Allen-Redpath K, Mitchell J, Fisk H Am J Clin Nutr. 2024; 119(5):1175-1186.

PMID: 38484976 PMC: 11130656. DOI: 10.1016/j.ajcnut.2024.03.008.

References

Vestad B, Llorente A, Neurauter A, Phuyal S, Kierulf B, Kierulf P . Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. J Extracell Vesicles. 2017; 6(1):1344087. PMC: 5533132. DOI: 10.1080/20013078.2017.1344087. View

Arraud N, Linares R, Tan S, Gounou C, Pasquet J, Mornet S . Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. J Thromb Haemost. 2014; 12(5):614-27. DOI: 10.1111/jth.12554. View

Gheldof D, Haguet H, Dogne J, Bouvy C, Graux C, George F . Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. J Thromb Thrombolysis. 2017; 43(2):224-232. DOI: 10.1007/s11239-016-1471-z. View

van der Pol E, Hoekstra A, Sturk A, Otto C, van Leeuwen T, Nieuwland R . Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost. 2010; 8(12):2596-607. DOI: 10.1111/j.1538-7836.2010.04074.x. View

Dragovic R, Gardiner C, Brooks A, Tannetta D, Ferguson D, Hole P . Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine. 2011; 7(6):780-8. PMC: 3280380. DOI: 10.1016/j.nano.2011.04.003. View

Kotze R, Ariens R, de Lange Z, Pieters M . CVD risk factors are related to plasma fibrin clot properties independent of total and or γ' fibrinogen concentration. Thromb Res. 2014; 134(5):963-9. DOI: 10.1016/j.thromres.2014.08.018. View

Koga H, Sugiyama S, Kugiyama K, Fukushima H, Watanabe K, Sakamoto T . Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. Eur Heart J. 2006; 27(7):817-23. DOI: 10.1093/eurheartj/ehi746. View

Reininger A, Heijnen H, Schumann H, Specht H, Schramm W, Ruggeri Z . Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood. 2006; 107(9):3537-45. PMC: 1895770. DOI: 10.1182/blood-2005-02-0618. View

Zahran A, Sayed S, Abd El Hafeez H, Khalifa W, Mohamed N, Hetta H . Circulating microparticle subpopulation in metabolic syndrome: relation to oxidative stress and coagulation markers. Diabetes Metab Syndr Obes. 2019; 12:485-493. PMC: 6469468. DOI: 10.2147/DMSO.S191750. View

10.

Al Dieri R, de Laat B, Hemker H . Thrombin generation: what have we learned?. Blood Rev. 2012; 26(5):197-203. DOI: 10.1016/j.blre.2012.06.001. View

11.

Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet J . Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol. 2006; 26(12):2775-80. DOI: 10.1161/01.ATV.0000249639.36915.04. View

12.

Ueba T, Nomura S, Inami N, Nishikawa T, Kajiwara M, Iwata R . Plasma level of platelet-derived microparticles is associated with coronary heart disease risk score in healthy men. J Atheroscler Thromb. 2010; 17(4):342-9. DOI: 10.5551/jat.2964. View

13.

Nomura S, Imamura A, Okuno M, Kamiyama Y, Fujimura Y, Ikeda Y . Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines. Thromb Res. 2000; 98(4):257-68. DOI: 10.1016/s0049-3848(00)00186-9. View

14.

Khot U, Khot M, Bajzer C, Sapp S, Ohman E, Brener S . Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290(7):898-904. DOI: 10.1001/jama.290.7.898. View

15.

Lee S, Chu K, Jung K, Kim J, Moon H, Bahn J . Circulating CD62E+ microparticles and cardiovascular outcomes. PLoS One. 2012; 7(4):e35713. PMC: 3338519. DOI: 10.1371/journal.pone.0035713. View

16.

Amabile N, Cheng S, Renard J, Larson M, Ghorbani A, McCabe E . Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study. Eur Heart J. 2014; 35(42):2972-9. PMC: 4223610. DOI: 10.1093/eurheartj/ehu153. View

17.

Bernal-Mizrachi L, Jy W, Jimenez J, Pastor J, Mauro L, Horstman L . High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J. 2003; 145(6):962-70. DOI: 10.1016/S0002-8703(03)00103-0. View

18.

Matsumoto S, Gotoh N, Hishinuma S, Abe Y, Shimizu Y, Katano Y . The role of hypertriglyceridemia in the development of atherosclerosis and endothelial dysfunction. Nutrients. 2014; 6(3):1236-50. PMC: 3967190. DOI: 10.3390/nu6031236. View

19.

Hozawa A, Folsom A, Sharrett A, Chambless L . Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects--Atherosclerosis Risk in Communities Study. Arch Intern Med. 2007; 167(6):573-9. DOI: 10.1001/archinte.167.6.573. View

20.

Orozco A, Lewis D . Flow cytometric analysis of circulating microparticles in plasma. Cytometry A. 2010; 77(6):502-14. PMC: 2919894. DOI: 10.1002/cyto.a.20886. View